Avalo Therapeutics Stock Alpha and Beta Analysis
| AVTX Stock | USD 9.55 0.44 4.40% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Avalo Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Avalo Therapeutics over a specified time horizon. Remember, high Avalo Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Avalo Therapeutics' market risk premium analysis include:
Beta (0.71) | Alpha 0.28 | Risk 6.2 | Sharpe Ratio 0.0447 | Expected Return 0.28 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Avalo |
Avalo Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Avalo Therapeutics market risk premium is the additional return an investor will receive from holding Avalo Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Avalo Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Avalo Therapeutics' performance over market.| α | 0.28 | β | -0.71 |
Avalo Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Avalo Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Avalo Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Avalo Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Avalo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Avalo Therapeutics shares will generate the highest return on investment. By understating and applying Avalo Therapeutics stock market price indicators, traders can identify Avalo Therapeutics position entry and exit signals to maximize returns.
Avalo Therapeutics Return and Market Media
The median price of Avalo Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 9.83 with a coefficient of variation of 18.2. The daily time series for the period is distributed with a sample standard deviation of 1.91, arithmetic mean of 10.51, and mean deviation of 1.62. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Avalo Announces Participation in September Investor Conferences | 09/04/2024 |
2 | Where are the Opportunities in - Stock Traders Daily | 09/24/2024 |
3 | Acquisition by Truex Samantha of 24600 shares of Avalo Therapeutics at 9.88 subject to Rule 16b-3 | 11/01/2024 |
4 | Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates | 11/07/2024 |
5 | Avalo Therapeutics Receives 69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants | 11/12/2024 |
6 | Acquisition by Almenoff June Sherie of 500 shares of Avalo Therapeutics at 13.0 subject to Rule 16b-3 | 11/13/2024 |
7 | Avalo Therapeutics director June Almenoff acquires 12,749 in stock | 11/14/2024 |
8 | Acquisition by Neil Garry Arthur of 4000 shares of Avalo Therapeutics at 3.42 subject to Rule 16b-3 | 11/18/2024 |
9 | Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN | 11/20/2024 |
About Avalo Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Avalo or other stocks. Alpha measures the amount that position in Avalo Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.44 | 1.19 | 2.88 | 4.46 | Days Of Inventory On Hand | 9.3 | 2.13 | 2.44 | 2.32 |
Avalo Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Avalo Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avalo Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Avalo Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Avalo Therapeutics. Please utilize our Beneish M Score to check the likelihood of Avalo Therapeutics' management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Avalo Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.